erlotinib hydrochloride has been researched along with mometasone furoate in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (mometasone furoate) | Trials (mometasone furoate) | Recent Studies (post-2010) (mometasone furoate) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 913 | 355 | 439 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | mometasone furoate (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2.9512 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
1 other study(ies) available for erlotinib hydrochloride and mometasone furoate
| Article | Year |
|---|---|
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |